Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Reducing Cardiovascular Events in TAVR Patients
NCT07090343Phase 3Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2026
- Primary completion
- Sep 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by Leiden University Medical Center. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07090343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090343.